Skip to main content
Top
Published in: Journal of Infection and Chemotherapy 6/2011

01-12-2011 | Original Article

Invasive Streptococcus pneumoniae infections in children in Kamikawa and Soya subprefecture, Hokkaido, Japan, 2000–2010, before the introduction of the 7-valent pneumococcal conjugate vaccine

Author: Hiroshi Sakata

Published in: Journal of Infection and Chemotherapy | Issue 6/2011

Login to get access

Abstract

We evaluated 103 cases of invasive pneumococcal disease (IPD) encountered in 99 children (two developed the disease twice and one, three times) treated in the northern district of Hokkaido (Kamikawa and Soya subprefecture) from April 2000 until March 2010, before the introduction of the 7-valent pneumococcal conjugate vaccine. The main diseases were as follows: pneumonia, 54 cases (52.9%); occult bacteremia, 34 cases (33.3%); meningitis, five cases (4.9%). There were 42 cases during the first half of the study period (from April 2000 to March 2005) and 61 during the second half (from April 2005 to March 2010). The IPD morbidity rate for the 10-year period was 41.3 per 100,000 population in children <5 years and 79.2 per 100,000 population in children <2 years. Serotype analysis of the 77 strains was performed. The most frequent serotype isolated was 6B (31.2%), followed by 23F (14.3%), 19F (13.0%), 9V (7.8%), 6A (7.8%), and 14 (3.9%). The number of strains that could potentially be covered by heptavalent pneumococcal conjugate vaccine was 55 (71.4%), and the number of strains that could potentially be covered by 13-valent pneumococcal conjugate vaccine was 64 (83.1%). Analysis of penicillin-binding protein (PBP) genes was performed of the 82 strains. The percentages of resistant bacteria caused by PBP gene mutations were 42.7% (35 strains) for gPRSP, 48.8% for gPISP (40 strains), and 8.5% for gPSSP (7 strains).
Literature
1.
go back to reference Sleeman K, Knox K, George R, Miller E, Waight P, Griffiths D, et al. Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis. 2001;183:239–46.PubMedCrossRef Sleeman K, Knox K, George R, Miller E, Waight P, Griffiths D, et al. Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis. 2001;183:239–46.PubMedCrossRef
2.
go back to reference Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998–2003. MMWR Morb Mortal Wkly Rep. 2005;54:893–7. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998–2003. MMWR Morb Mortal Wkly Rep. 2005;54:893–7.
3.
go back to reference Dias R, Caniça M. Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine. FEMS Immunol Med Microbiol. 2007;51:35–42.PubMedCrossRef Dias R, Caniça M. Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine. FEMS Immunol Med Microbiol. 2007;51:35–42.PubMedCrossRef
4.
go back to reference O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893–902.PubMedCrossRef O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893–902.PubMedCrossRef
5.
go back to reference Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14:e197–209.PubMedCrossRef Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14:e197–209.PubMedCrossRef
6.
go back to reference Ubukata K, Chiba N, Hasegawa K, Kobayashi R, Iwata S, Sunakawa K. Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002. Antimicrob Agents Chemother. 2004;48:1488–94.PubMedCrossRef Ubukata K, Chiba N, Hasegawa K, Kobayashi R, Iwata S, Sunakawa K. Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002. Antimicrob Agents Chemother. 2004;48:1488–94.PubMedCrossRef
7.
go back to reference Ishiwada N, Kurosaki T, Terashima I, Kohno Y. The incidence of pediatric invasive pneumococcal disease in Chiba prefecture, Japan (2003–2005). J Infect. 2008;57:455–8.PubMedCrossRef Ishiwada N, Kurosaki T, Terashima I, Kohno Y. The incidence of pediatric invasive pneumococcal disease in Chiba prefecture, Japan (2003–2005). J Infect. 2008;57:455–8.PubMedCrossRef
8.
go back to reference Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998. JAMA. 2001;285:1729–35.PubMedCrossRef Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998. JAMA. 2001;285:1729–35.PubMedCrossRef
9.
go back to reference Ispahani P, Slack RC, Donald FE, Weston VC, Rutter N. Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation. Arch Dis Child. 2004;89:757–62.PubMedCrossRef Ispahani P, Slack RC, Donald FE, Weston VC, Rutter N. Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation. Arch Dis Child. 2004;89:757–62.PubMedCrossRef
10.
go back to reference Pineda V, Fontanals D, Larramona H, Domingo M, Anton J, Segura F, et al. Epidemiology of invasive Streptococcus pneumoniae infections in children in an area of Barcelona, Spain. Acta Paediatr. 2002;91:1251–6.PubMedCrossRef Pineda V, Fontanals D, Larramona H, Domingo M, Anton J, Segura F, et al. Epidemiology of invasive Streptococcus pneumoniae infections in children in an area of Barcelona, Spain. Acta Paediatr. 2002;91:1251–6.PubMedCrossRef
11.
go back to reference Chiba N, Morozumi M, Sunaoshi K, Takahashi S, Takano M, Komori T, et al. Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol Infect. 2010;138:61–6.PubMedCrossRef Chiba N, Morozumi M, Sunaoshi K, Takahashi S, Takano M, Komori T, et al. Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol Infect. 2010;138:61–6.PubMedCrossRef
12.
go back to reference Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7:e1000348.CrossRef Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7:e1000348.CrossRef
13.
go back to reference Aguiar SI, Brito MJ, Gonçalo-Marques J, Melo-Cristino J, Ramirez M. Serotypes 1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use. Vaccine. 2010;28:5167–73.PubMedCrossRef Aguiar SI, Brito MJ, Gonçalo-Marques J, Melo-Cristino J, Ramirez M. Serotypes 1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use. Vaccine. 2010;28:5167–73.PubMedCrossRef
14.
go back to reference Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010;28:4249–59.PubMedCrossRef Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010;28:4249–59.PubMedCrossRef
Metadata
Title
Invasive Streptococcus pneumoniae infections in children in Kamikawa and Soya subprefecture, Hokkaido, Japan, 2000–2010, before the introduction of the 7-valent pneumococcal conjugate vaccine
Author
Hiroshi Sakata
Publication date
01-12-2011
Publisher
Springer Japan
Published in
Journal of Infection and Chemotherapy / Issue 6/2011
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-011-0264-8

Other articles of this Issue 6/2011

Journal of Infection and Chemotherapy 6/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine